Advanced non-squamous NSCLC with no actionable oncogenic driver in Spain: a cross-sectional descriptive analysis of data from the Thoracic Tumor Registry
Clinical and Translational Oncology · 2024
DOI: 10.1007/s12094-024-03511-7 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift Clinical and Translational Oncology, 2024. Verfasst von Enric Carcereny und 20 weiteren Autor:innen. Beteiligte Einrichtung: Institut Català D'oncologia Badalona- Hospital Germans Trias I Pujol, B-Argo Group, Badalona, Spain. ecarcereny@iconcologia.net. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Registries. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Non-small cell lung cancer (NSCLC) accounts for the vast majority of all diagnosed lung cancers. According to their histology, most NSCLCs are considered non-squamous cell carcinoma (NSCC), and up to 85% of the latter may lack either one of the two main actionable oncogenic drivers (i.e., EGFR mutations and ALK rearrangements). OBJECTIVE: Our analysis aimed to describe the clinical and epidemiological characteristics of Spanish patients suffering from NSCC with no actionable oncogenic driver in daily clinical practice. DESIGN: A retrospective, cross-sectional, descriptive analysis. METHODS: We analyzed the records of all Spanish patients with advanced NSCC diagnosed between January 2011 and January 2020 and included in the Spanish Thoracic Tumor Registry database. We evaluated the presence of metastasis and molecular profiling at the time of diagnosis and treatments received. We also assessed overall survival (OS) and progression-free survival (PFS) according to first-line treatment. RESULTS: One thousand seven hundred ninety-seven Spanish patients with NSCC were included. They were mainly men (73.2%), smokers (current [44.4%] and former [44.4%]) and presented adenocarcinoma histology (97.6%). Most patients had at least one comorbidity (80.4%) and one metastatic site (96.8%), and a non-negligible number of those tested were PD-L1 positive (35.2%). Notably, the presence of liver metastasis indicated a shorter median OS and PFS than metastasis in other locations (p < 0.001). Chemotherapy was more often prescribed than immunotherapy as first-, second-, and third-line treatment in that period. In first-line, the OS rates were similar in patients receiving either regimen, but PFS rates significantly better in patients treated with immunotherapy (p = 0.026). Also, a high number of patients did not reach second- and third-line treatment, suggesting the failure of current early diagnostic measures and therapies. CONCLUSIONS: This analysis of the most lethal tumor in Spain could highlight the strengths and the weaknesses of its clinical management and set the ground for further advances and research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institut Català D'oncologia Badalona- Hospital Germans Trias I Pujol, B-Argo Group, Badalona, Spain. ecarcereny@iconcologia.net.
- Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain.
- Hospital Clínico Universitario de Valladolid, Valladolid, Spain.
- Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.
- Hospital General Universitario de Elche, Elche, Spain.
- Hospital General Universitario Dr. Balmis de Alicante, Alicante, Spain.
Zitieren
APA
Carcereny, E., Rodriguez-Abreu, D., Lopez, R., Franco, F., Guirado, M., Massutí, B., Cobo, M., Blasco, A., Suay, G., Del Barco, E., Ortega, A. L., Sala, M. A., Cordeiro, P., Bernabé, R., González Larriba, J. L., Bosch-Barrera, J., Calzas, J., Casal, J., Padilla, A., …, & Provencio, M. (2024). Advanced non-squamous NSCLC with no actionable oncogenic driver in Spain: a cross-sectional descriptive analysis of data from the Thoracic Tumor Registry. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-024-03511-7
Vancouver
Carcereny E, Rodriguez-Abreu D, Lopez R, Franco F, Guirado M, Massutí B, et al. Advanced non-squamous NSCLC with no actionable oncogenic driver in Spain: a cross-sectional descriptive analysis of data from the Thoracic Tumor Registry. Clinical and Translational Oncology. 2024. doi:10.1007/s12094-024-03511-7
BibTeX
@article{Carcereny2024,
author = {Carcereny, Enric and Rodriguez-Abreu, Delvys and Lopez, Rafael and Franco, Fabio and Guirado, Maria and Massutí, Bartomeu and Cobo, Manuel and Blasco, Ana and Suay, Guillermo and Del Barco, Edel and Ortega, Ana Laura and Sala, Maria Angeles and Cordeiro, Patricia and Bernabé, Reyes and González Larriba, José Luís and Bosch-Barrera, Joaquim and Calzas, Julia and Casal, Joaquín and Padilla, Airam and Sánchez-Hernandez, Alfredo and Provencio, Mariano},
title = {Advanced non-squamous NSCLC with no actionable oncogenic driver in Spain: a cross-sectional descriptive analysis of data from the Thoracic Tumor Registry},
journal = {Clinical and Translational Oncology},
year = {2024},
doi = {10.1007/s12094-024-03511-7}
}
EUVIMED